A Phase 2 Study of Tarlatamab for People With Advanced Prostate Cancer

Full Title

Purpose

Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the best treatments for prostate cancers that have metastasized (spread).

The benefits of hormone treatments do not last, however. Over time, many prostate cancers keep growing, even with hormonal therapies. These are called castration-resistant prostate cancers (CRPC). Some prostate cancers develop mutations and transform to a disease called neuroendocrine prostate cancer (NEPC).

Researchers are assessing tarlatamab to treat CRPC and NEPC. The people in this study have prostate cancer that keeps growing or metastasized after treatment. In addition, their tumors must have high levels of a protein called DLL3. It is more common to find DLL3 on tumors with NEPC.

Tarlatamab works by binding to two different proteins. It attaches to DLL3 on cancer cells and to T cells in the immune system. By directing your immune cells to DLL3, tarlatamab may strengthen your immune system’s ability to fight cancer cells. It is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

• Have CRPC or NEPC that keeps growing even though you received treatment for metastatic prostate cancer.
• Have completed prior anti-cancer therapies at least 2 weeks before starting the study treatment.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Karen Autio’s office at 646-422-4632.